GlassScriptPhysician profile
Tammy M Smith
NPI 1720006315
$688.17
in general payments reported to CMS, 2019-2025
12 companies · $549 in 2025
The $549 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.94 · 2023: $39.59 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $190.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $171.31 | 2023-2025 | |
| Lilly USA, LLC | $152.28 | 2021-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.75 | 2025 | Caplyta |
| Dexcom, INC. | $24.46 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $21.72 | 2023 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.08 | 2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $18.25 | 2025 | Qelbree |
| Organon LLC | $17.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.19 | 2021 | |
| Exact Sciences Corporation | $15.05 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $14.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.